Evidence map›Paper›PMID 23875929›Full record

ArticleBMC ear, nose, and throat disorders2013

Hidden consequences of olfactory dysfunction: a patient report series.

Andreas Keller, Dolores Malaspina

4 registry-linked trialsAbstract read
In one paragraph

Article in BMC ear, nose, and throat disorders, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 92 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
92citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05445921 phase1 / phase2completednot on this mapstarted 2022, after this paper: background citation

Stellate Ganglion Block for the Treatment of COVID-19-Induced Olfactory Dysfunction: A Prospective Pilot Study

TypeinterventionalSponsorWashington University School of MedicineRan2022 to 2022Enrolled20ConditionsAnosmia, Hyposmia, Parosmia, Olfactory DisorderArmsStellate Ganglion Block
NCT06055270 phase3unknown statusnot on this mapstarted 2024, after this paper: background citation

Stellate Ganglion Block With Lidocaine for the Treatment of COVID-19-Induced Parosmia: Double-Blinded, Placebo-Controlled Randomized Clinical Trial

TypeinterventionalSponsorLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sRan2024 to 2026Enrolled44ConditionsParosmiaArmsStellate Ganglion Block, Placebo
NCT06253806 phase2completednot on this mapstarted 2023, after this paper: background citation

Stellate Ganglion Block for the Treatment of COVID-19-Induced Parosmia: Double-Blinded, Placebo-Controlled Randomized Clinical Trial

TypeinterventionalSponsorWashington University School of MedicineRan2023 to 2024Enrolled48ConditionsCOVID-19-Induced ParosmiaArmsStellate Ganglion Block, Placebo Sham Injection
NCT06498687 phase1withdrawnnot on this mapstarted 2025, after this paper: background citation

A Single-Arm Study to Evaluate the Feasibility of CYR-064 Theophylline Nasal Spray for the Treatment of Parkinson's Disease Related Hyposmia and Anosmia

TypeinterventionalSponsorUniversity of NebraskaRan2025 to 2026Enrolled0ConditionsHyposmia, AnosmiaArmsCYR-064
3 · Its place in the literature

Who cites it

92 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Is loss of sense of smell a diagnostic marker in COVID-19: A systematic review and meta-analysis.Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery · 2020
    Pooled it
  5. Olfactory dysfunction in acute rhinosinusitis: intranasal sodium hyaluronate as adjuvant treatment.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2017
    Trial
  6. Trial
  7. Trial
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Parosmia: Pathophysiology and Management.Current allergy and asthma reports · 2025
    Review
  17. Article
  18. Article
  19. Article
  20. Article

32 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Andreas KellerLaboratory of Neurogenetics and Behavior, Rockefeller University, New York, NY, USA. Andreas.Keller@rockefeller.edu.
Dolores Malaspina

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe negative consequences of olfactory dysfunction for the quality of life are not widely appreciated and the condition is therefore often ignored or trivialized.

methods1,000 patients with olfactory dysfunction participated in an online study by submitting accounts of their subjective experiences of how they have been affected by their condition. In addition, they were given the chance to answer 43 specific questions about the consequences of their olfactory dysfunction.

resultsAlthough there are less practical problems associated with impaired or distorted odor perception than with impairments in visual or auditory perception, many affected individuals report experiencing olfactory dysfunction as a debilitating condition. Smell loss-induced social isolation and smell loss-induced anhedonia can severely affect quality of life.

conclusionsOlfactory dysfunction is a serious condition for those affected by it and it deserves more attention from doctors who treat affected patients as well as from scientist who research treatment options.

Identifiers

PMID23875929
PMCPMC3733708

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.